Suzhou Highfine Biotech Co., Ltd.

Suzhou Highfine Biotech Co., Ltd. is a high-tech enterprise specializing in the research and development, production, and sales of peptide synthesis reagents. Founded in 2003 and listed on the ChiNext board of the Shenzhen Stock Exchange in 2023, the company has established itself as a key player in the raw chemical materials and chemical products manufacturing sector. Highfine Biotech focuses on providing a comprehensive range of synthesis reagents essential for the amide bond formation in the development and production of small molecule and peptide drugs. The company's product portfolio includes peptide synthesis reagents, general-purpose molecular building blocks, and protein reagents, all of which are supported by a robust core technology system. Highfine Biotech also actively engages in emerging markets, developing high-value products such as liposome pharmaceutical reagents and PROTAC reagents. With a diverse customer base exceeding 1,900 pharmaceutical R&D and manufacturing enterprises, including major multinational corporations, the company is well-positioned to meet the evolving demands of the global pharmaceutical industry while maintaining strong customer loyalty through its technical capabilities and rapid response services.

1、Strong Technical Service & Rapid Response Founded in 2003, Highfine is one of the early high-tech enterprises in China specializing in the R&D, production, and sales of peptide synthesis reagents. After nearly two decades of development, it has accumulated extensive R&D achievements in the field of organic synthesis. It has established a complete and independent core technology system in R&D and production of products such as peptide synthesis reagents, general-purpose molecular building blocks, and protein reagents. These strong technical capabilities not only enhance product quality and market competitiveness but also enable the R&D team to quickly develop customized synthesis processes for special customer needs, providing diverse tailored services that drive the company’s sustainable growth. With most main products in stock, the company ensures rapid response to customer demands, a critical advantage in the time-sensitive pharmaceutical industry. 2、Diverse Product Portfolio & High Added Value As an upstream service provider in the bio-pharmaceutical industry, the company leverages the brand advantage of its comprehensive, high-performance peptide synthesis reagents to rapidly introduce molecular building blocks and protein reagents with broader market demand and higher technical barriers. It also actively expands into emerging fields such as liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids, PROTAC reagents, and nucleotide reagents. This rich product matrix serves as the core vehicle for technology industrialization, fully meeting the procurement needs of downstream customers in the bio-pharmaceutical sector. 3、Extensive Customer Base & Strong Loyalty Highfine serves over 1,900 domestic and foreign pharmaceutical R&D and manufacturing enterprises, as well as CROs and CDMOs, including multinational giants like Bachem AG and Lonza, and leading Chinese outsourcing firms such as WuXi AppTec, Asymchem, and PharmaBlock. These customers have strict supplier certification processes, and once a trusting partnership is established, it tends to be stable and deepening over time. 4、Talented Team & Strong Brand As one of China’s early movers in peptide synthesis reagent R&D/production and protein reagent development, the company has built a professional, stable R&D team with over 20 years of experience in technology industrialization, capable of delivering customized solutions and professional services. Core technical staff possess deep expertise in peptide synthesis reagent R&D and production. With over two decades of focus on peptide synthesis reagents, the company has gained recognition at home and abroad. Its industry strength and influence make it a preferred partner for downstream customers seeking peptide synthesis reagents.